Apotex Inc. has followed Sandoz in urging the Supreme Court to review an appeals court ruling that delays the launch of a biosimilar until six months after FDA licensure.
Apotex filed a petition on Sept. 9 challenging the US Court of Appeals for the Federal Circuit's decision...





